A phase IIIB study evaluating the effect on serum lipids following a switch to atazanavir in HIV infected subjects evidencing virologic suppression on their first PI [protease inhibitor]-based antiretroviral therapy

Trial Profile

A phase IIIB study evaluating the effect on serum lipids following a switch to atazanavir in HIV infected subjects evidencing virologic suppression on their first PI [protease inhibitor]-based antiretroviral therapy

Completed
Phase of Trial: Phase III

Latest Information Update: 27 Apr 2011

At a glance

  • Drugs Atazanavir; HIV protease inhibitors
  • Indications HIV-1 infections
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Bristol-Myers Squibb
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 22 Dec 2005 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top